StockNews.com downgraded shares of Cencora (NYSE:COR – Free Report) from a strong-buy rating to a buy rating in a research report released on Thursday morning.
A number of other research firms have also issued reports on COR. Citigroup lifted their target price on Cencora from $265.00 to $280.00 and gave the stock a buy rating in a report on Tuesday, April 30th. Mizuho lifted their target price on Cencora from $192.00 to $224.00 and gave the stock a neutral rating in a report on Monday, February 5th. Barclays started coverage on Cencora in a report on Wednesday, January 3rd. They set an overweight rating and a $242.00 target price on the stock. SVB Leerink started coverage on Cencora in a report on Monday, February 26th. They set an outperform rating and a $261.00 target price on the stock. Finally, Leerink Partnrs reaffirmed an outperform rating on shares of Cencora in a report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $233.90.
Check Out Our Latest Stock Report on Cencora
Cencora Price Performance
Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The business had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same period in the previous year, the business earned $3.50 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. Equities analysts expect that Cencora will post 13.44 EPS for the current year.
Cencora Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, May 24th. Investors of record on Friday, May 10th will be paid a $0.51 dividend. The ex-dividend date is Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.91%. Cencora’s dividend payout ratio is currently 22.32%.
Insider Buying and Selling at Cencora
In other Cencora news, EVP Elizabeth S. Campbell sold 6,977 shares of Cencora stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the transaction, the executive vice president now owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Cencora news, EVP Elizabeth S. Campbell sold 6,977 shares of Cencora stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the transaction, the executive vice president now owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total value of $2,553,859.92. Following the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $67,702,698.24. The disclosure for this sale can be found here. Insiders have sold a total of 4,288,790 shares of company stock valued at $1,009,641,379 in the last 90 days. 15.80% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Cencora
Several institutional investors have recently made changes to their positions in COR. Vanguard Group Inc. acquired a new stake in shares of Cencora during the 4th quarter valued at about $4,212,508,000. Bank of New York Mellon Corp acquired a new stake in shares of Cencora during the 1st quarter valued at about $291,825,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Cencora during the 1st quarter valued at about $238,457,000. Principal Financial Group Inc. acquired a new stake in shares of Cencora during the 1st quarter valued at about $75,916,000. Finally, Cornerstone Investment Partners LLC acquired a new stake in shares of Cencora during the 1st quarter valued at about $73,653,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
- Five stocks we like better than Cencora
- Most active stocks: Dollar volume vs share volume
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- Using the MarketBeat Stock Split Calculator
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- Best Stocks Under $10.00
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.